

### AMENDMENTS TO THE CLAIMS


Please cancel claims 1-23 and 29-32 without prejudice.

Pursuant to 37 C.F.R. § 1.121(c)(1), please amend claim 1.

Please add new claims 33-35.

#### Claims 1-23 (Cancelled)

24. (Original) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR<sub>7</sub>, -SR<sub>7</sub>, a halogen or -N(R<sub>9</sub>)R<sub>10</sub>;

R<sub>9</sub> and R<sub>10</sub>, each independently, represent -H, alkyl, alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>7</sub>, or R<sub>9</sub> and R<sub>10</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R<sub>7</sub> represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises W, Y, and a heterocycle having from 4 to about 8 atoms in the ring structure, optionally aromatic and optionally substituted. a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

25. (Original) The coordination complex of claim 24, wherein W is N.

26. (Original) The coordination complex of claim 24, wherein Pt is Pt(II).

27. (Original) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 24 and a pharmaceutically acceptable carrier.

28. **(Original)** The pharmaceutical composition of claim 27, wherein said coordination complex is ammine(2-amino-3-picoline)dichloroplatinum(II).

Claims 29-32 **(Cancelled)**

33. **(New)** The coordination complex of claim 24, wherein V is a 6-membered aromatic heterocycle.

34. **(New)** The coordination complex of claim 33, wherein V is pyridine or a substituted pyridine.

35. **(New)** The coordination complex of claim 33, wherein V is picoline or a substituted picoline.

36. **(New)** The coordination complex of claim 24, wherein Pt is Pt(IV) and two additional ligands in the trans axial positions are present.

37. **(New)** The coordination complex of claim 36, wherein said each of said additional ligands comprise a carboxylate group.

38. **(New)** A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 36 and a pharmaceutically acceptable carrier.

39. **(New)** The pharmaceutical composition of claim 38, wherein said coordination complex is ammine(2-amino-3-picoline)dichlorodiacetoplatinum(IV).

40. **(New)** The coordination complex of claim 24, wherein both X are halogens.

41. **(New)** The coordination complex of claim 40, wherein said halogen is chlorine.

42. **(New)** The coordination complex of claim 24, wherein both X comprise a carboxylate group.

43. **(New)** The coordination complex of claim 42, wherein said carboxylate group is a chelating dicarboxylate.


44. **(New)** The coordination complex of claim 42, wherein at least one X is acetate.

45. **(New)** The coordination complex of claim 24, wherein L is an amine having the structure NR<sub>2</sub>(R<sub>3</sub>), wherein R<sub>2</sub> and R<sub>3</sub> each independently represent a hydrogen, an alkyl, an alkenyl, -

(CH<sub>2</sub>)<sub>m</sub>-R<sub>4</sub>, or R<sub>2</sub> and R<sub>3</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; and wherein R<sub>2</sub> represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8.

46. (New) The coordination complex of claim 24, wherein L is an ammine.

47. (New) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR<sub>7</sub>, -SR<sub>7</sub>, a halogen or -N(R<sub>9</sub>)R<sub>10</sub>;

R<sub>9</sub> and R<sub>10</sub>, each independently, represent -H, alkyl, alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>7</sub>, or R<sub>9</sub> and R<sub>10</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R<sub>7</sub> represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;


wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

48. (New) The coordination complex of claim 47, wherein each of X is a halogen.

49. (New) The coordination complex of claim 48, wherein said halogen is chlorine.

50. (New) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 47 and a pharmaceutically acceptable carrier.

51. (New) A coordination complex, comprising: a structure represented by the formula:



wherein, independently for each occurrence:

X represents halogen or other labile ligand;

W represents S, N, or P;

Y represents -OR<sub>7</sub>, -SR<sub>7</sub>, a halogen or -N(R<sub>9</sub>)R<sub>10</sub>;

R<sub>9</sub> and R<sub>10</sub>, each independently, represent -H, alkyl, alkenyl, -(CH<sub>2</sub>)<sub>n</sub>-R<sub>7</sub>, or R<sub>9</sub> and R<sub>10</sub>, taken together with the N atom to which they are attached complete a heterocycle having from 4 to about 8 atoms in the ring structure, all optionally substituted;

L represents a non-labile ligand; and

R<sub>7</sub> represents -H, alkyl, aryl, cycloalkyl, cycloalkenyl, heterocycle or polycycle;

wherein the ligand V comprises a heterocycle, optionally aromatic and optionally substituted, that comprises the atoms W and Y and has from 4 to about 8 atoms in the ring structure.

52. (New) A pharmaceutical composition, comprising: a therapeutically effective amount of a coordination complex of claim 51 and a pharmaceutically acceptable carrier.